Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
The complement system, a proteolytic cascade within innate immunity, is tightly regulated during healthy gestation to support implantation, placental development and parturition while preventing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results